Updated Feb. 19, 2013 at 1:25 p.m.

Premium Lock GSK, partner Theravance target December for heart disease drug decision

Published: 2013-02-19 13:20:00
Updated: 2013-02-19 13:25:26

GSK GSK

GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) said Tuesday that the New Drug Application (NDA) for a  investigational combination medicine to treat patients with chronic obstructive pulmonary disease (COPD) has been accepted by the U.S. Food and Drug Administration....



Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll